Imupeg 6mg Injection

About

Imupeg 6mg Injection is a pegylated form of granulocyte colony-stimulating factor (G-CSF), a naturally occurring protein that stimulates the bone marrow to produce more white blood cells, specifically neutrophils. By increasing neutrophil counts, Imupeg helps to reduce the incidence and duration of febrile neutropenia, a serious complication of myelosuppressive chemotherapy that significantly increases the risk of severe infection. It provides sustained neutrophil support with a single dose per chemotherapy cycle, thereby allowing patients to maintain their chemotherapy schedules and improving overall treatment outcomes.

Uses

• Reduction of chemotherapy-induced neutropenia.
• Prevention of febrile neutropenia.
• Management of severe chronic neutropenia.
• Used after bone marrow transplantation to aid recovery.

Directions For Use

Administer subcutaneously as a single dose per chemotherapy cycle, typically 24-72 hours after chemotherapy completion, as directed by a healthcare professional.

Benefits

• Significantly reduces the risk of febrile neutropenia.
• Decreases the incidence of infection during chemotherapy.
• Allows for on-schedule chemotherapy regimens.
• Improves patient outcomes and reduces hospitalizations.
• Convenient once-per-chemotherapy-cycle dosing.
• Stimulates rapid recovery of neutrophil counts.

Side Effects

• Bone pain.
• Muscle pain (myalgia).
• Headache.
• Fatigue.
• Nausea.
• Injection site reactions (pain, redness).
• Splenic enlargement (rare).
• Acute respiratory distress syndrome (rare).
• Allergic reactions.
• Leukocytosis (high white blood cell count).
• Thrombocytopenia (low platelet count).
• Elevated lactate dehydrogenase (LDH).

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but general health advice to limit alcohol intake during chemotherapy applies.
• Pregnancy - Use Imupeg during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult your doctor.
• Breastfeeding - Use with caution during breastfeeding as it is unknown if pegfilgrastim is excreted in human milk. Consult a doctor.
• Liver - No specific dose adjustment is generally needed for patients with liver impairment. Monitor for any adverse effects.
• Kidney - No specific dose adjustment is generally needed for patients with kidney impairment. Monitor for any adverse effects.
• Lung - Monitor for pulmonary adverse reactions, including acute respiratory distress syndrome (ARDS) and interstitial lung disease, which are rare but serious.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.